Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7495343 | 1.00 | MME (0.39) | MMENPC1PTGS1FNTAFNTB | |
| SCHEMBL21002274 | 0.83 | GRIN2D (0.31) | — | |
| SCHEMBL21002272 | 0.83 | GRIN2D (0.31) | — | |
| SCHEMBL1137769 | 0.81 | CYP2C19 (0.39) | ALDH1A1POLBCDC25A | |
| SCHEMBL6542942 | 0.81 | TSHR (0.38) | FNTAFNTBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL11639405 | 0.80 | CYP2C19 (0.42) | ALDH1A1POLBCDC25A | |
| SCHEMBL11474662 | 0.80 | PTPN1 (0.35) | ALDH1A1 | |
| SCHEMBL12541025 | 0.78 | MME (0.35) | MMENPC1 | |
| SCHEMBL3539164 | 0.77 | GRIN1 (0.36) | POLB | |
| SCHEMBL15043702 | 0.77 | GRIN1 (0.36) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993459-B1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6410541-B2 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES ADMINISTERED AS ANTITUMOR AGENTS | SCHERING CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-20010007870-A1 | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents | REMISZEWSKI STACY W (US) | 2001-07-12 | — | — | US | disclosed |
| US-6211193-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES; ANTITUMOR AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-0993459-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998057955-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007870-A1 | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents | HCCS, FNTB, CBR1 | MME 4048/4885NPC1 56/4885PTGS1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.